170414 ⎘
Assays involving biological materials from specific organisms or of a specific nature from animals; from humans; Assays involving cytokines; Chemokines Alpha-chemokines, e.g. NAP-2, ENA-78, GRO-alpha/MGSA/NAP-3, GRO-beta/MIP-2alpha, GRO-gamma/MIP-2beta, IP-10, GCP-2, MIG, PBSF, PF-4 or KC
ANAKINRA FOR THE TREATMENT OF POST ACUTE COVID SYNDROME
#2USE OF EMAPALUMAB FOR TREATMENT
#3TGF-BETA INHIBITORS AND USE THEREOF
#4BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT CONDITIONS
#5Atomic Description of Immune Complex that Causes Heparin-Induced Thrombocytopenia
#6METHODS OF USING TUMOR INFILTRATING LYMPHOCYTES IN DOUBLE-REFRACTORY MELANOMA
#7GENE EXPRESSION MARKERS AND TREATMENT OF MULTIPLE SCLEROSIS
#8Atomic description of immune complex that causes heparin-induced thrombocytopenia
#9METHODS AND MATERIALS FOR IDENTIFYING AND TREATING MONOCLONAL AND OLIGOCLONAL GAMMOPATHIES
#10PRODUCTS AND METHODS FOR THE DIAGNOSIS AND DIFFERENTIATION OF HEPARIN-INDUCED THROMBOCYTOPENIA FROM VACCINE-INDUCED IMMUNE THROMBOTIC THROMBOCYTOPENIA AND NON-HEPARIN-INDUCED THROMBOCYTOPENIA
#11Methods and Compositions for Diagnosis and Prognosis of Renal Injury and Renal Failure
#12Methods for Diagnosing and/or Predicting the Risk of Having an Acute Rejection (AR) in a Kidney Transplant Recipient
#13Atomic description of immune complex that causes heparin-induced thrombocytopenia
#14METHODS OF DIAGNOSING AND CLASSIFYING VIRAL INFECTIONS
#15IN VITRO METHOD FOR DISCRIMINATING LATENT FROM ACTIVE TUBERCULOSIS
#16COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING ALZHEIMERS DISEASE
#17Biomarkers of neutrophil deregulation as diagnostic for gingivitis
#18BIOMARKERS FOR DETERMINING SURVIVAL AND THERAPEUTIC RESPONSE IN CERVICAL CANCER
#19METHODS OF DIAGNOSING TUBERCULOSIS AND DIFFERENTIATING BETWEEN ACTIVE AND LATENT TUBERCULOSIS
#20Gene expression markers and treatment of multiple sclerosis
#21Atypical hemolytic uremic syndrome (AHUS) biomarker proteins
#22Endogenous Labelling of Extracellular Vesicles
#23Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
#24DETECTING CANCER WITH ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES
#25INHIBITORS OF PROTEINS SPECIFIC FOR THE SECRETOME OF A CHONDROCYTE FOR USE IN THE TREATMENT OF BREAST CANCER METASTASIS
#26Atomic description of immune complex that causes heparin-induced thrombocytopenia
#27MATERIAL AND METHODS FOR DIAGNOSING AND TREATING KAWASAKI DISEASE AND KLS
#28Methods of using tumor infiltrating lymphocytes in double-refractory melanoma
#29Method of altering an antibody-related adverse event based on SCD163 and/or CXCL5 levels
#30Methods for detecting, diagnosing and treating ulcerative interstitial cystitis
#31Biomarker signatures for lyme disease differentiation and methods of use thereof
#32Signatures and determinants for diagnosing infections and methods of use thereof
#33Biomarkers for assessing risk of transitioning to systemic lupus erythematosus classification and disease pathogenesis
#34Activation assay for the diagnosis of a heparin-induced thrombocytopenia
#35Method and kit for determining the probability that a patient will develop a severe case of dengue
#36Method of treating cervical neoplasia in patients infected with human papilloma virus
#37CXCL10 AS PREDICTIVE BIOMARKER OF RENAL TRANSPLANT ACUTE REJECTION AND DIAGNOSTIC BIOMARKER OF ANTIBODY-MEDIATED REJECTION (ABMR)
#38CXCL13 AS AN INDICATOR OF GERMINAL ACTIVITY AND IMMUNE RESPONSE
#39Gene expression markers and treatment of multiple sclerosis
#40Atomic description of immune complex that causes heparin-induced thrombocytopenia
#41ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS) BIOMARKER PROTEINS
#42Levels of CXCL10/IP-10 forms and soluble CD26/DPPIV activity as early predictive biomarkers for HIV/SIV associated mucosal inflammation and progression towards AIDS
#43Biomarkers and assay to detect chronic graft versus host disease
#44Methods for determining the concentration of an analyte in solution
#45Diagnosis and treatment of Kawasaki disease
#46METHODS FOR DIAGNOSIS AND PROGNOSIS OF INFLAMMATORY BOWEL DISEASE USING CYTOKINE PROFILES
#47METHODS OF MEASURING ANTIGEN-SPECIFIC T CELLS
#48METHODS OF DIAGNOSING CELIAC DISEASE USING IP-10
#49Atypical hemolytic uremic syndrome (aHUS) biomarker proteins
#50Method and kit for determining the probability that a patient will develop a severe case of dengue
#51Methods for detecting and treating cancer
#52METHODS FOR DIAGNOSING, SCREENING, IDENTIFYING, MONITORING, AND TREATING ADVERSE LOCAL TISSUE REACTIONS, WHICH LEAD TO FAILURE OF ORTHOPEDIC IMPLANTS
#53METHOD FOR DIAGNOSING AN INFLAMMATORY CONDITION IN THE FEMALE GENITAL TRACT
#54Atypical hemolytic uremic syndrome (AHUS) biomarker proteins
#55Antibody and Cytokine Biomarker Profiling for Determination of Patient Responsiveness
#56BIOMARKERS FOR THE DIAGNOSIS AND THE RESPONSE TO TREATMENT OF PANCREATIC CANCER
#57Systems and methods for characterizing kidney diseases
#58Methods for determining responsiveness to an anti-CD47 agent
#59Inhibitors of proteins specific for the secretome of a chondrocyte for use in the treatment of breast cancer metastasis
#60HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disorders
#61BIOMARKERS FOR OVARIAN CANCER
#62Levels of CXCL 10/IP-10 forms and soluble CD26/DPPIV activity as early predictive biomarkers for HIV/SIV associated mucosal inflammation and progression towards AIDS
#63MATERIAL AND METHODS FOR DIAGNOSING AND TREATING KAWASAKI DISEASE AND KLS
#64Methods for detecting heparin/platelet factor 4 antibodies
#65Method of Simultaneous Detection of Heparin-Induced Immunoglobulins Types G, A and M
#66METHODS AND KITS FOR DIAGNOSING HEPARIN-INDUCED THROMBOCYTOPENIA
#67DETECTING CANCER WITH ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES
#68CXCL5 AS A MARKER OF HORMONE ESCAPE IN PROSTATE CANCER
#69BIOMARKERS FOR LOWER URINARY TRACT SYMPTOMS (LUTS)
#70Methods for diagnosing degenerative joint disease
#71Methods and compositions for diagnosis and prognosis of renal injury and renal failure
#72HMGB1 and anti-HMGB1 antibodies for the prognostic of neurological disorders
#73Systems and methods for characterizing kidney diseases
#74NOVEL ASSAY FOR DETECTING IMMUNE RESPONSES INVOLVING ANTIGEN SPECIFIC CYTOKINE AND/OR ANTIGEN SPECIFIC CYTOKINE SECRETING T-CELLS
#75DETECTING CANCER WITH ANTI-CXCL13 AND ANTI-CXCR5 ANTIBODIES
#76BIOMARKERS FOR PREDICTING SUSTAINED RESPONSE TO HCV TREATMENT
#77Methods for detecting and treating cancer
#78Immunoassay method for human CXCL1 protein
#79Methods of Using SDF-1 (CXCL12) as a Diagnostic and Mesenchymal Stem Cell (Multipotent Stromal Cell)-Specific Therapeutic Biomarker for the Treatment of Kidney Injury and Other Major Organs
#80METHODS FOR DETERMINING THE CONCENTRATION OF AN ANALYTE IN SOLUTION
#81Rapid and sensitive method for quantitative determination of the level of heparin—PF4 complex induced immunoglobulin antibodies
#82SYSTEMS AND METHODS FOR CHARACTERIZING KIDNEY DISEASE
#83Molecular phenotyping of severe asthma
#84Compositions and methods for detecting and treating prostate disorders
#85Antibody profiling for determination of patient responsiveness
#86Systems and methods for characterizing kidney diseases
#87Methods and kits for detecting heparin/platelet factor 4 antibodies
#88Systems and methods for characterizing kidney diseases
#89Peptides for use in treatment and diagnosis of type 1 diabetes